Current Issue 2018  Archive 2017 
Biography
Biography

Editor-in-Chief of OBM Hepatology and Gastroenterology

Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine.

Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.

Biography

The Associate Editor of OBM Hepatology and Gastroenterology

Tatsuo Kanda received a medical degree in 1991 at Niigata University School of Medicine, Japan, and his PhD in 1999 at Chiba University Graduate School of Medicine, Japan. He had post-doctor training for 3 years under Prof. Ratna Ray and Prof. Ranjit Ray at Saint Louis University, St. Louis, MO, USA. In Dec. 2008, Tatsuo Kanda became a Tenure-track Associate Professor at Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Japan. In Feb. 2013, Tatsuo Kanda was nominated a permanent Associate Professor at Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Japan. In 2017, Tatsuo Kanda became an Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine. For ~25 years, he has focused his scientific interests on the topics related to liver diseases including acute liver failure, viral hepatitis and autoimmune liver diseases, and worked with Prof. Osamu Yokosuka. Tatsuo Kanda is also an expert for hepatitis A virus (HAV), HBV and HCV, and translation and replication of these viruses, and hepatocarcinogenesis. With his expertise in antiviral therapies and hepatitis virus research, Tatsuo Kanda also sees a lot of patients in clinical daily practice. Tatsuo Kanda has published more than 200 articles in peer-reviewed Journal.

Special Issue

Multiple Aspects of Transplant Tolerance – Mechanisms, Strategies, and Barriers

Submission Deadline: September 30, 2018 (Open)                Submit Now

Guest Editor

Jean Kwun, PhD
Assistant Professor of Surgery, Duke Transplant Center, Department of Surgery, Duke University Medical Center, 207 Research Dr, Jones 362, Durham, NC 27710, USA
E-Mail: [email protected]
Website: https://surgery.duke.edu/faculty/jean-kwun-phd
Research Interests: heart transplantation, transplant tolerance, humoral tolerance to organ transplants, mechanisms of antibody-mediated rejection (AMR), establishing a conceptual basis that will translate into therapeutic intervention of AMR

About This Topic

The idea of immunological tolerance was developed from seminal works by Ray Owen, Sir F. MacFarlane Burnet, and Sir Peter Medawar in the mid-20th century. These findings drove transplantation research to identify mechanisms of immune tolerance. However, despite partial success, it was unable to stably induce tolerance in immunocompetent recipients. In the special issue, “Multiple Aspects of Transplant Tolerance”, we will provide a forum for presenting mechanisms, strategies, and challenges for promoting tolerance in transplantation. This will include description of cell populations plays a crucial role in tolerance as well as cell-based approaches (Treg, Mreg, DCreg, CD8 Treg, Tr1, and not excluding BM, apoptotic cell-based strategies), identification/validation of clinical tolerance strategy and biomarkers. Finally, we will also cover B cell immunobiology in transplantation and strategies for B cell and plasma cell tolerance. The special issue will also be open to any author, but mainly invited by guest editor. Each submission will be reviewed by at least two reviewers to ensure a very high quality of papers selected for the Special Issue.

Planned Papers

Title: Innate Immune Tolerance in Allo-transplantation
Authors: Andrea Carrion-Webster MD, Sunil Joshi DVM PhD, Asha Pillai MD

Title: Cell Based Therapies in Transplant Tolerance
Authors: Byoung Chol Oh, Giorgio Raimondi, Michael Grzelak

Title: Tolerance in Clinical Liver Transplantation
Authors: Daniel Azoulay and Salim Hamdani

Title: Medawar's Paradox and Immune Mechanisms of Fetomaternal Tolerance
Authors: Victoria R. Rendell, MD and Todd V. Brennan, MD MS

Title: Clinical Tolerance induction trials – Where do we stand?
Authors: Antje Habicht, Joachim Andrassy

Title: T Cell Exhaustion: A Novel Mechanism of Transplant Tolerance
Authors: Zubair Ilyas, Mohammed Javeed I Ansari

Title: Antibody-Based Therapies in Transplant Tolerance
Authors: Maite Van Hentenryck, Zhanzhuo Li, Patricia Favaro, Philip Murphy, Agnieszka Czechowicz

Title: Innate Mechanisms of MHC- independent Transplant Tolerance
Authors: Sunil Joshi, Asha Pillai

Title: Induction of tolerance using hematopoietic cell transplantation in large animal models
Authors: Scott S. Graves, Rainer Storb, David Mathes, Bruce Swearingen

Title: Prospects for Tolerance in Vascularized Composite Allotransplantation
Authors: Nicole M. Shockor, Arthur J. Nam, Stephen T. Bartlett, Rolf N. Barth
Affiliation: University of Maryland School of Medicine

Title: PRESENT AND FUTURE STRATEGIES FOR THE TREATMENT OF HEREDITARY HEMOGLOBINOPATHIES
Authors: Vanessa Gonçalves de Oliveira 1, Ana Filipa Saraiva 2, Fátima Costa 2, Aida Botelho de Sousa 2
Affiliations: 1. Transfusion Medicine Unit, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal;
2. Hematology and Hematopoietic Stem Cell Transplant Unit, Hospital Santo António dos Capuchos, Centro Hospitalar de Lisboa Central (CHLC), Lisbon, Portugal.
Abstract: Nowadays, hematopoietic stem cell transplantation (HSCT) is a common procedure in Hematology Units within Reference Centres, mainly for the treatment of hematological malignancies such as multiple myeloma, lymphoma and acute leukemia. Nevertheless, HSCT has much wider applications namely in autoimmune diseases, congenital metabolic defects and hemoglobinopathies. Thalassemia major and sickle cell disease comprise, altogether, the most frequent hereditary hemoglobinopathies worldwide. Despite the advances on the prevention and treatment of complications related to these diseases, still, the only curative approach available resides in allogeneic HSCT. The main challenges of this treatment remain focused on the toxicity of pre-transplant conditioning regimens and short-term transplant related complications like graft-versus-host disease, infections and disease recurrence. Thus, it is crucial to establish a balance between the risk vs benefit of HSCT for each patient and follow the available guidelines for both diseases. Recently, gene therapy is becoming a real alternative to allogeneic HSCT. Recent advances in molecular biology methods have provided more accurate and reliable gene editing techniques such as the CRISP/CAS9 system. The long-term outcome of gene manipulation procedures remains uncertain, especially in the immune system of the host. This review will focus on HSCT and gene therapy in hereditary hemoglobinopathies.

Title: Potential role of high-dose cyclophosphamide for tolerance in solid organ transplantation
Author: Roberto Crocchiolo

Title: Thymus tissue engineering to induce transplantation tolerance
Author: Yong Fan

Title: Role of regulatory T cell in Transplant Tolerance
Author: Annalisa Paviglianiti

Publication

Opinion

The Holy Grail to Clinical Transplant Tolerance Is Paved with HLA Epitopes

Rene J. Duquesnoy
Received: July 11, 2018; Published: September 6, 2018; doi:10.21926/obm.transplant.1803018